Browse by Journal Title

2022

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla, G. and Radecke, C. and Frentsch, M. and Walther, W. and Stintzing, S. and Riess, H. and Bullinger, L. and Na, I.K.
OncoImmunology 11 (1): 2068109. 25 April 2022

2020

Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.
Pötzsch, M. and Berg, E. and Hummel, M. and Stein, U. and von Winterfeld, M. and Jöhrens, K. and Rau, B. and Daum, S. and Treese, C.
OncoImmunology 9 (1): 1824632. 30 September 2020

2019

Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors.
Kaffes, I. and Szulzewsky, F. and Chen, Z. and Herting, C.J. and Gabanic, B. and Velázquez Vega, J.E. and Shelton, J. and Switchenko, J.M. and Ross, J.L. and McSwain, L.F. and Huse, J.T. and Westermark, B. and Nelander, S. and Forsberg-Nilsson, K. and Uhrbom, L. and Maturi, N.P. and Cimino, P.J. and Holland, E.C. and Kettenmann, H. and Brennan, C.W. and Brat, D.J. and Hambardzumyan, D.
OncoImmunology 8 (11): e1655360. 22 August 2019

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.
Penter, L. and Dietze, K. and Ritter, J. and Lammoglia Cobo, M.F. and Garmshausen, J. and Aigner, F. and Bullinger, L. and Hackstein, H. and Wienzek-Lischka, S. and Blankenstein, T. and Hummel, M. and Dornmair, K. and Hansmann, L.
OncoImmunology 8 (6): e1586409. 24 March 2019

2017

Labeling of cell therapies: How can we get it right?
Waiczies, S. and Niendorf, T. and Lombardi, G.
OncoImmunology 6 (10): e1345403. 20 July 2017

The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.
Stache, V. and Verlaat, L. and Gätjen, M. and Heinig, K. and Westermann, J. and Rehm, A. and Höpken, U.E.
OncoImmunology 6 (6): e1323155. 6 June 2017

2016

Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer, D. and Grünewald, T.G.P. and Klar, R. and Schmidt, O. and Wohlleber, D. and Rubio, R.A. and Uckert, W. and Thiel, U. and Bohne, F. and Busch, D.H. and Krackhardt, A.M. and Burdach, S. and Richter, G.H.S.
OncoImmunology 5 (6): e1175795. 25 April 2016

Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.
Mensali, N. and Ying, F. and Sheng, V.O.Y. and Yang, W. and Walseng, E. and Kumari, S. and Fallang, L.E. and Kolstad, A. and Uckert, W. and Malmberg, K.J. and Waelchli, S. and Olweus, J.
OncoImmunology 5 (5): e1138199. 18 February 2016

2012

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: gene gun is superior to jet injector in inducing CTL responses and protective immunity.
Nguyen-Hoai, T. and Kobelt, D. and Hohn, O. and Vu, M.D. and Schlag, P.M. and Doerken, B. and Norley, S. and Lipp, M. and Walther, W. and Pezzutto, A. and Westermann, J.
OncoImmunology 1 (9): 1537-1545. 1 December 2012